Product Portfolio header Spectrum Pharmaceuticals Product Portfolio picture
   
Oncology, Generics, Neurology Drugs About Spectrum Pharmaceuticals SPPI Investor Relations SPPI News
shadow area

RenaZorb™

Second generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology

Target Indication
  • Hyperphosphatemia in End Stage Renal Disease (ESRD) and potentially Chronic Kidney Disease (CKD)

Route of Administration
  • Oral (swallow tablet)

RenaZorb Mode of Action
  • Lanthanum-based phosphate binding agent
  • Non-calcium, non-aluminum phosphate binder utilizing proprietary nanoparticle technology

RenaZorb Status
  • Preclinical
RenaZorb - Chains of Nanoparticles

Scanning Electron Micrograph (SEM) of RenaZorb™

Hyperphosphatemia Market

There are an estimated 340,000 end stage renal disease (ESRD) patients in the U.S. who are on kidney dialysis. The market for phosphate binding agents was approximately $500 million in 2006. According to the National Kidney Foundation, the number of ESRD patients in the U.S. is expected to double over the next decade.

There are an estimated 8.4 million chronic kidney disease (CKD) patients who are candidates for phosphate binder therapy according to the National Kidney Foundation

[Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines, issued in 2003]

Renazorb™ is available for outlicensing outside the U.S.

back to top

Advanced Search  |  Home  |  Site Map  |  Contact Us  |  WebMail

 All contents © Copyright Spectrum Pharmaceuticals, Inc. 2008. All Rights Reserved.  Terms of Use